*Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-0934, Japan.
Jpn J Clin Oncol. 2014 Jan;44(1):9-12. doi: 10.1093/jjco/hyt188. Epub 2013 Dec 25.
Met is a tyrosine kinase that has hepatocyte growth factor as its ligand. Met plays a major role in cell growth, migration and morphological changes. Overexpression of hepatocyte growth factor and Met and mutations and amplification of MET have been noted in many forms of cancer and are reportedly correlated with cancer progression and a poor prognosis. Over the past few years, these molecules have attracted attention as targets of molecularly targeted therapies. This article describes the association relationship between hepatocyte growth factor/Met and cancer and it describes the latest findings regarding inhibitors to target hepatocyte growth factor/Met that are currently being developed.
Met 是一种酪氨酸激酶，其配体是肝细胞生长因子。Met 在细胞生长、迁移和形态变化中起主要作用。在许多形式的癌症中都观察到肝细胞生长因子和 Met 的过表达以及 MET 的突变和扩增，据报道，这些与癌症进展和预后不良有关。在过去的几年中，这些分子作为分子靶向治疗的靶点引起了人们的关注。本文描述了肝细胞生长因子/Met 与癌症之间的关联关系，并描述了目前正在开发的针对肝细胞生长因子/Met 的抑制剂的最新发现。
